Member AUM
$70 trillion
Report Background

Antimicrobial Resistance & Antibiotic Stewardship in the Animal Pharmaceutical Industry

Animal Pharmaceuticals Engagement: 2022/23 Progress Report






Screenshot-2023-05-19-at-16.37.14-1




22 May 2023
Antibiotics & Health

Report Overview

In May 2022, FAIRR launched an investor engagement campaign aimed at driving greater disclosure and clarity over how - and if - animal pharmaceutical companies are addressing antimicrobial resistance (AMR) risk throughout their value chains. This engagement seeks to address the misuse and overuse of antibiotics in animal agriculture, which accounts for over two-thirds of the world's sales of antibiotics and has led to rising concerns over the development of AMR. 

As AMR’s negative impact on global health becomes more apparent, it is increasingly important for animal pharmaceutical companies to demonstrate that they are taking proactive steps to address this issue. This includes reducing any unnecessary use of antibiotics in animal agriculture, investing in alternative products, and developing robust antimicrobial stewardship programs.

This report highlights the lack of transparency and disclosure from animal pharmaceutical companies on their practices related to antibiotics and AMR. Thus hindering investors and other stakeholders from understanding the risks and opportunities associated with these companies. 

Report Highlights

The findings of this report can help investors:

  • Understand that AMR is a material risk to diversified portfolios.

  • Understand what key risks animal pharmaceutical companies are exposed to.

  • Gauge how animal pharmaceutical companies demonstrate their preparedness to tackle the risks of AMR and/or to benefit from the growth opportunity presented by developing alternative solutions to antibiotics. 

  • Compare and contrast disclosures of the engagement companies across five detailed engagement pillars.

  • Access best practice examples across the five engagement pillars.

Downloads

Key Findings

NON-MEMBERS
MEMBERS
  • Brief overview of the engagement 

  • Key takeaways from each engagement pillar

Overview of antimicrobial resistance (AMR) and its material risks

Overview of the animal pharmaceutical industry

Company performance at a glance

Detailed company analysis by engagement pillar

Best practice examples

Recommendations for companies

Investor Call to Action

Progress Report

MEMBERS
  • Overview of antimicrobial resistance (AMR) and its material risks

  • Overview of the animal pharmaceutical industry

  • Company performance at a glance

  • Detailed company analysis by engagement pillar

  • Best practice examples

  • Recommendations for companies

  • Investor Call to Action

Progress Report